Lei Kunyang, Wang Xu, Yang Zhongsheng, Liu Yifu, Sun Ting, Xie Wenjie, Ma Ming
Department of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Department of Pathology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Front Oncol. 2023 Feb 22;13:1043753. doi: 10.3389/fonc.2023.1043753. eCollection 2023.
To compare the efficacy and safety of retroperitoneal laparoscopic adrenalectomy (RLA) and transperitoneal laparoscopic adrenalectomy (TLA) in the treatment of large (≥6cm) adrenal pheochromocytomas.
We retrospectively collected the clinical data of 130 patients with large pheochromocytoma who underwent RLA or TLA in our hospital from 2012 to 2022. The perioperative parameters and follow-up outcomes of the two groups were compared, and univariate and multivariate analyses were used to evaluate the risk factors of hemodynamic instability (HI).
A total of 57 patients underwent TLA and 73 underwent RLA. There was no difference in demographic characteristics such as age, sex and tumor size between the two groups. Compared with the TLA group, patients in the RLA group had shorter operation time (P<0.001) and less estimated blood loss (EBL) (P<0.001). The time to ambulation, time to oral food and time to removal of drainage of RLA group were earlier than those of TLA group. In addition, the hospital stay was shorter in the RLA group than in the TLA group. There were no differences in HI, complications, or blood pressure (BP) improvement between the two groups. The mean follow-up time was 61.4 and 65.5 months, respectively, during which no tumors recurred or metastasized. Multivariate analysis showed that elevated hormone levels and larger tumor size were independent risk factors for HI.
Both RLA and TLA are effective treatment methods for large pheochromocytomas, but the perioperative outcomes of RLA are better than that of TLA. Our study demonstrates the superiority of RLA for the treatment of large pheochromocytomas.
比较后腹腔镜肾上腺切除术(RLA)和经腹腹腔镜肾上腺切除术(TLA)治疗大型(≥6cm)肾上腺嗜铬细胞瘤的疗效和安全性。
回顾性收集2012年至2022年在我院接受RLA或TLA的130例大型嗜铬细胞瘤患者的临床资料。比较两组的围手术期参数和随访结果,并采用单因素和多因素分析评估血流动力学不稳定(HI)的危险因素。
共有57例患者接受了TLA,73例接受了RLA。两组在年龄、性别和肿瘤大小等人口统计学特征方面无差异。与TLA组相比,RLA组患者的手术时间更短(P<0.001),估计失血量(EBL)更少(P<0.001)。RLA组的下床活动时间、进食时间和引流管拔除时间均早于TLA组。此外,RLA组的住院时间比TLA组短。两组在HI、并发症或血压(BP)改善方面无差异。平均随访时间分别为61.4个月和65.5个月,在此期间无肿瘤复发或转移。多因素分析显示,激素水平升高和肿瘤体积较大是HI的独立危险因素。
RLA和TLA都是治疗大型嗜铬细胞瘤的有效方法,但RLA的围手术期结果优于TLA。我们的研究证明了RLA在治疗大型嗜铬细胞瘤方面的优越性。